TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous Melanoma-Reference-Cited by-同舟云学术

TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous Melanoma

Published:2014-09 Issue:9 Volume:106 Page:
ISSN:1460-2105
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Griewank Klaus G.,Murali Rajmohan,Puig-Butille Joan Anton,Schilling Bastian,Livingstone Elisabeth,Potrony Miriam,Carrera Cristina,Schimming Tobias,Möller Inga,Schwamborn Marion,Sucker Antje,Hillen Uwe,Badenas Celia,Malvehy Josep,Zimmer Lisa,Scherag André,Puig Susana,Schadendorf Dirk

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/106/9/dju246/17313809/dju246.pdf

Reference32 articles.

1. Mutations of the BRAF gene in human cancer;Davies;Nature,2002

2. Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity?;Albino;Nature,1984

3. Somatic activation of KIT in distinct subtypes of melanoma;Curtin;J Clin Oncol,2006

4. Distinct sets of genetic alterations in melanoma;Curtin;N Engl J Med,2005

5. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma;Guldberg;Cancer Res,1997

Cited by 209 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomas;European Journal of Cancer;2024-09

2. Advances in Melanoma: From Genetic Insights to Therapeutic Innovations;Biomedicines;2024-08-14

3. Utility and Micro-Costing Framework for TERT Promoter Mutation Analysis in Melanocytic Lesions of Uncertain Malignant Potential: A Retrospective Study in Dutch Local Clinical Practice;Diagnostics;2024-08-01

4. Using deep learning to decipher the impact of telomerase promoter mutations on the dynamic metastatic morpholome;PLOS Computational Biology;2024-07-30

5. Therapeutic targeting of PLK1 in TERT promoter‐mutant hepatocellular carcinoma;Clinical and Translational Medicine;2024-05